Table 3.
US | Norway | Spain | |
---|---|---|---|
(1996–2008) n =2,656,834 % (95 % CI) | (1996–2007) 1,470,854 % (95 % CI) | (1996–2009) 1,585,906 % (95 % CI) | |
Sensitivity | 83.1 (82.4 − 83.7) | 75.5 (74.7 − 76.4) | 79.0 (78.1 − 79.9) |
Specificity | 91.3 (91.2 − 91.3) | 97.1 (97.1 − 97.1) | 96.2 (96.2 − 96.2) |
PPV-1 | 4.9 (4.8 − 5.0) | 16.4 (16.0 − 16.7) | 9.8 (9.8 − 9.8) |
1/PPV-1 | 20.3 (20.0 − 20.7) | 6.1 (6.0 − 6.2) | 10.2 (10.2 − 10.3) |
PPV-2 | 25.9a (25.4 − 26.4) | 39.4 (38.7 − 40.1) | 38.9 (38.9 − 38.9) |
1/PPV-2 | 3.9 (3.8 − 3.9) | 2.5 ( 2.5 − 2.6) | 2.6 (2.6 − 2.6) |
aUS data do not capture all biopsies: the number of women who were recommended to receive a biopsy, defined as BI-RADS assessment at the end of all imaging workup of 4 or 5, or BI-RADS assessment of 0 or 3 accompanied by recommendation for biopsy, FNAC, or surgical consult is thus reported